These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34434503)

  • 1. Correction: Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach.
    Xiao Z; Sperl B; Gärtner S; Nedelko T; Stacher-Priehse E; Ullrich A; Knyazev PG
    Oncotarget; 2021 Aug; 12(17):1734-1735. PubMed ID: 34434503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach.
    Xiao Z; Sperl B; Gärtner S; Nedelko T; Stacher-Priehse E; Ullrich A; Knyazev PG
    Oncotarget; 2019 Apr; 10(26):2546-2560. PubMed ID: 31069016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M
    Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines.
    Boopathy GTK; Lynn JLS; Wee S; Gunaratne J; Hong W
    Cell Signal; 2018 Mar; 43():21-31. PubMed ID: 29196224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction:
    Madic J; Jovelet C; Lopez J; André B; Fatien J; Miran I; Honoré A; Mezquita L; Besse B; Lacroix L; Droniou M
    Oncotarget; 2019 Feb; 10(13):1345. PubMed ID: 30863495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
    Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
    Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR.
    Yu XD; Yang R; Leng CJ
    Comput Biol Chem; 2016 Apr; 61():251-7. PubMed ID: 26967626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization.
    Li N; Wei M
    Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):1023-1028. PubMed ID: 27346601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
    Xu N; Fang W; Mu L; Tang Y; Gao L; Ren S; Cao D; Zhou L; Zhang A; Liu D; Zhou C; Wong KK; Yu L; Zhang L; Chen L
    Oncotarget; 2018 Oct; 9(81):35284. PubMed ID: 30443296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.
    Menezes SV; Kovacevic Z; Richardson DR
    J Biol Chem; 2019 Mar; 294(11):4045-4064. PubMed ID: 30679310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I γ Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6.
    Sun M; Cai J; Anderson RA; Sun Y
    J Biol Chem; 2016 Oct; 291(41):21461-21473. PubMed ID: 27557663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
    Zhang H; Liu W; Wang Z; Meng L; Wang Y; Yan H; Li L
    Tumori; 2018 Jun; 104(3):221-231. PubMed ID: 29714661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mig6 reduces inflammatory mediators production by regulating the activation of EGFR in LPS-induced endotoxemia.
    Chen W; Zhong H; Wang X; Pang Q; Zhuang J; Hu J; Chen Y; Hu J; Liu J; Tang J
    J Cell Physiol; 2018 Sep; 233(9):6975-6983. PubMed ID: 29336487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.
    Zhang H; Zhan C; Ke J; Xue Z; Zhang A; Xu K; Shen Z; Yu L; Chen L
    Oncotarget; 2018 Oct; 9(81):35285. PubMed ID: 30443297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: S100A9+ MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB.
    Feng PH; Yu CT; Chen KY; Luo CS; Wu SM; Liu CY; Kuo LW; Chan YF; Chen TT; Chang CC; Lee CN; Chuang HC; Lin CF; Han CL; Lee WH; Lee KY
    Oncotarget; 2018 Jul; 9(59):31559. PubMed ID: 30140390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis.
    Izumchenko E; Sidransky D
    Cancer Discov; 2015 May; 5(5):472-4. PubMed ID: 25941338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling.
    Park SY; Choi HK; Seo JS; Yoo JY; Jeong JW; Choi Y; Choi KC; Yoon HG
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2722-30. PubMed ID: 26239118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations.
    Zhang Y; Zheng QC
    J Theor Biol; 2018 Jun; 447():118-125. PubMed ID: 29574142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer.
    Shields S; Conroy E; O'Grady T; McGoldrick A; Connor K; Ward MP; Useckaite Z; Dempsey E; Reilly R; Fan Y; Chubb A; Matallanas DG; Kay EW; O'Connor D; McCann A; Gallagher WM; Coppinger JA
    Oncotarget; 2019 May; 10(33):3144. PubMed ID: 31139326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
    Siu MK; Abou-Kheir W; Yin JJ; Chang YS; Barrett B; Suau F; Casey O; Chen WY; Fang L; Hynes P; Hsieh YY; Liu YN; Huang J; Kelly K
    Oncotarget; 2018 Aug; 9(64):32403. PubMed ID: 30190798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.